![[fetch_key]](https://stocktradeupdates.com/wp-content/uploads/new_logos/AARTIPHARM.png)
Share the post "Aarti Pharmalabs ‘s Q3 2024-25 Latest News: Profit Rises by 40.24% YoY"
Highlights
🔹 The presented financial data is Consolidated to provide a comprehensive overview of the company performance. 🔹 Sales over the Year and quarter: The company experienced a substantial growth of 19.86 % in the past year, substantial increase in net sales/revenue by 17.41 %. 🔹 Income over the Year and quarter: There has been either a marginal increase or a decline in other income over the past year which is 260.69 %. Marginal increase in other income during this quarter, up by 12.16%. 🔹 Profit over the Year and quarter: Significant improvement in profitability for Aarti Pharmalabs Limited. Notable increase of 40.22 % in net profit Year to Year, Aarti Pharmalabs Limited’s profitability increased by 35.45 % in this quarter. 🔹 EPS over the Year and quarter: EPS increased by 40.21 % Year to Year. EPS increased by 35.32 % in previous quarter. Positive impact on shareholders.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 448.689 Cr | Rs. 458.026 Cr | Rs. 537.778 Cr | + 17.41 % | + 19.86 % |
| Expenses | Rs. 353.01 Cr | Rs. 364.35 Cr | Rs. 409.17 Cr | + 12.3 % | + 15.91 % |
| Operating Profit | Rs. 95.68 Cr | Rs. 93.68 Cr | Rs. 128.61 Cr | + 37.29 % | + 34.42 % |
| OPM % | 21.32 % | 20.45 % | 23.92 % | + 3.47 % | + 2.6 % |
| Other Income | Rs. 1.394 Cr | Rs. 4.483 Cr | Rs. 5.028 Cr | + 12.16 % | + 260.69 % |
| Interest | Rs. 4.48 Cr | Rs. 5.51 Cr | Rs. 9.97 Cr | + 80.94 % | + 122.54 % |
| Depreciation | Rs. 18.77 Cr | Rs. 20.88 Cr | Rs. 23.04 Cr | + 10.34 % | + 22.75 % |
| Profit before tax | Rs. 73.82 Cr | Rs. 71.77 Cr | Rs. 100.63 Cr | + 40.21 % | + 36.32 % |
| Tax % | 28.52 % | 23.89 % | 26.47 % | + 2.58 % | -2.05 % |
| Net Profit | Rs. 52.76 Cr | Rs. 54.62 Cr | Rs. 73.99 Cr | + 35.46 % | + 40.24 % |
| EPS in Rs | Rs. 5.82 | Rs. 6.02 | Rs. 8.16 | + 35.55 % | + 40.21 % |
Today, we’re looking at Aarti Pharmalabs Limited’s financial performance for the Q3(Dec 2024-25).Starting with the top line, the company reported a robust year-over-year sales growth of 19.86 %. However, it did see a marginal increase of 17.41 % from the previous quarter. Expenses ticked up slightly by 12.3 % quarter-on-quarter, aligning with the annual rise of 15.91 %. Operating profit, while up 34.42 % compared to last year, faced a quarter-on-quarter increase of 37.29 %, signaling a short-term expansion in margins.
The Operating Profit Margin (OPM) % echoes this narrative, showing resilience on an annual basis with an increase of 2.6 %, but an expansion of 3.47 % sequentially. Other income rose by 12.16 % compared to the last quarter, despite an annual growth of 260.69 %. Interest expenses surged remarkably by 80.94 % from the previous quarter, yet the year-over-year increase remains at a moderate 122.54 %. Depreciation costs climbed by 10.34 % quarter-on-quarter, whereas on an annual scale, they saw an increase of 22.75 %. Profit before tax grew annually by 36.32 % but saw an increase from the preceding quarter by 40.21 %.
Tax expenses as a percentage of profits decreased slightly by -2.05 % compared to last year, with a more notable quarter-on-quarter increase of 2.58 %. Net profit rose by 40.24 % year-on-year but experienced a 35.46 % expansion from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual uptick of 40.21 % but a quarterly rise of 35.55 %. In summary, Aarti Pharmalabs Limited’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 448.689 Cr | Rs. 458.026 Cr | Rs. 537.778 Cr | + 17.41 % | + 19.86 % |
| Expenses | Rs. 353.01 Cr | Rs. 364.35 Cr | Rs. 409.17 Cr | + 12.3 % | + 15.91 % |
| Operating Profit | Rs. 95.68 Cr | Rs. 93.68 Cr | Rs. 128.61 Cr | + 37.29 % | + 34.42 % |
| Net Profit | Rs. 52.76 Cr | Rs. 54.62 Cr | Rs. 73.99 Cr | + 35.46 % | + 40.24 % |
| EPS in Rs | Rs. 5.82 | Rs. 6.02 | Rs. 8.16 | + 35.55 % | + 40.21 % |
In reviewing Aarti Pharmalabs Limited’s 2024-25(Q3) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales saw a robust 19.86 % year-on-year growth, however, there was a minor increase of 17.41 % from the previous quarter. Expenses rose by 15.91 % compared to the previous year, with a 12.3 % increase quarter-on-quarter. Operating Profit surged by 34.42 % annually, and saw a 37.29 % increase from the last quarter.
Net Profit showed yearly increase of 40.24 %, and experienced a 35.46 % increase from the previous quarter. Earnings Per Share (EPS) rose by 40.21 % annually, however rose by 35.55 % compared to the last quarter. In essence, while Aarti Pharmalabs Limited exhibits strong annual growth indicators, short-term improvements suggest the potential for recovery and the importance of strategic adjustments to counter market challenges effectively. That’s all for now in the financial sector.
![[fetch_key]](https://stocktradeupdates.com/wp-content/uploads/new_logos/RAMRAT.png)